Another meta-analysis by Liao et al.,32which included six RCTs involving T2DM patients,5, 55, 64, 75, 76, 77consistently found that GLP-1 receptor agonists (various subtypes vs. placebo) were associated with an increased risk of DVT (55/20,598 vs. 25/20,608; RR 2.12, 95% CI 1.32–3.40). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.